Rhinitis News and Research

RSS

Rhinitis, commonly known as a runny nose, is the medical term describing irritation and inflammation of some internal areas of the nose. The primary symptom of rhinitis is nasal dripping. It is caused by chronic or acute inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants.

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Guidelines to help people with allergies during bad weather

As this winter continue to take many parts of the country on a temperature roller coaster ride—from seasonal bone-chilling cold to springlike warmth and then back again—many people find themselves reaching for pain relievers or other remedies to deal with runny noses and other symptoms associated with sinus and allergy problems.

31 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Soligenix's OrbeShield granted FDA oral BDP orphan drug designation

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

2 Jan 2013

HAL Allergy completes enrollment in SUBLIVAC FIX Phleum pratense Phase II trial

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC FIX Phleum pratense.

19 Dec 2012

Asthma and nasal congestion common insomnia triggers

Insomnia is a common problem in patients with asthma, suggests research published in Allergy.

30 Nov 2012

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

Allergies common in ADHD, tic disorder patients

A significant number of people with attention deficit/hyperactivity disorder and tic disorder also have one or more allergic diseases such as asthma or atopic dermatitis, show study results.

23 Nov 2012

Nasal spray sufficient for allergic rhinitis in Japanese patients

Intranasal corticosteroid sprays can be administered as a first-line treatment for Japanese patients with seasonal allergic rhinitis, without the need to use systemic corticosteroid drugs, suggest study findings.

20 Nov 2012

General guidelines to understand allergic skin conditions

Winter months can bring on the itch as cold weather and indoor heat dry out the skin. It's possible, suggests Chicago allergist, Brian Rotskoff, MD of Clarity Allergy Center, that your winter itch could be caused by more than just the weather. For some people itchy, dry skin is just that, but for others it can be a symptom of atopic dermatitis (eczema), contact dermatitis, or hives (urticaria).

16 Nov 2012

Triclosan exposure linked to allergies in children

Norwegian children with high levels of urinary triclosan are more likely to have allergies than children with lower levels, report researchers in Allergy.

15 Nov 2012

Triclosan can contribute to increased risk of allergies in children

Triclosan - an antibacterial chemical found in toothpaste and other products - can contribute to an increased risk of allergy development in children. This comes from the Norwegian Environment and Childhood Asthma Study, in which the Norwegian Institute of Public Health is involved. Similar results are reported in the USA.

15 Nov 2012

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).

8 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Santarus, Inc. and Pharming Group NV today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met the primary endpoint of time to beginning of symptom relief.

7 Nov 2012

Allergic rhinitis common in otitis media patients

Allergic rhinitis is a common comorbidity in children with otitis media with effusion, suggest study findings.

2 Nov 2012

Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigation

Mylan Inc. today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.

10 Oct 2012

Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers

Could it be that those with allergic rhinitis (hay fever) and childhood nasal allergies can finally get a break from their allergies and their allergy shots? Chicago's leading allergy, asthma, and immunology expert, Dr. Brian Rotskoff, who treats a large number of Chicago pediatric allergy patients, is happy to say, "Yes!"

5 Oct 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012